GlassScriptPhysician profile
Christopher Gerald Cann
NPI 1124552898
$5,817.30
in general payments reported to CMS, 2019-2025
11 companies · $3,438 in 2025
The $3,438 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,845 · 2024: $535 · 2025: $3,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,409 · Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,409.00 |
| Food and Beverage | $1,408.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $4,109.00 | 2023-2025 | |
| Regeneron Pharmaceuticals, INC. | $659.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $458.81 | 2024-2025 | Imfinzi |
| Gilead Sciences, INC. | $209.43 | 2024-2025 | Trodelvy |
| Eisai INC. | $131.98 | 2024-2025 | |
| Intera Oncology, INC | $107.25 | 2024 | Intera |
| Tempus Ai, INC | $48.40 | 2024-2025 | Xt Cdx |
| Astellas Pharma US INC | $27.80 | 2024 | Xospata |
| Ipsen Biopharmaceuticals, INC | $24.77 | 2025 | Somatuline Depot, Onivyde |
| Beone Medicines USA, INC. | $24.39 | 2025 | Tevimbra |
| Glaxosmithkline, LLC. | $16.47 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.